Phase II
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 23, 2021.
It was a relatively quiet week in terms of clinical trial news, but there were some significant releases. Here’s a look.
It will evaluate about 440 patients and the treatments’ effect on liver fibrosis improvement and NASH resolution.
Infectious disease-focused Vaccitech, which partnered with AstraZeneca and Oxford University on the development and manufacturing of that company’s COVID-19 vaccine, raised $168 million in a Series B financing round.
Topline data from Merck KGaA’s Phase II INTR@PID BTC 047 study show bintrafusp alfa has single-agent efficacy and safety in the second-line treatment of locally advanced or metastatic biliary tract cancer in patients who have either failed or are intolerant to first-line platinum-based chemotherapy.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 16, 2021.
Nearly five years to the day after striking the deal, AVEO Oncology and CANbridge Life Sciences announce the termination of their collaboration and licensing agreement for AVEO’s AV-203.
Two of the biggest drugmakers in the HIV space are teaming up on a combination therapy that has the potential to be a game-changer for patients diagnosed with the dangerous virus for which there is no known cure.
Many drugs for Alzheimer’s disease have demonstrated promise in early and mid-stage clinical trials, but then go on to fail in larger late-stage trials. It’s too early to know if that will be the case with Eli Lilly’s donanemab, but it showed unusually good primary results in a Phase II trial, with decidedly mixed secondary endpoint results.
It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson’s disease, Alzheimer’s, HIV and more.
PRESS RELEASES